 |
|
|
| |
REAL-WORLD SAFETY AND EFFECTIVENESS OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR AND GLECAPREVIR/PIBRENTASVIR IN HEPATITIS C INFECTED PATIENTS
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Varun Saxena, MD, MAS1,2; Scott Chamberland, PharmD3; Leo Hurley, MPH4; Jennifer B. Lai, MSC, PharmD5; Elizabeth Truong, PharmD3; Julia Marcus, PhD, MPH6;
Jamila Champsi, MD1; Brad Hare, MD7; Daniel Korn, MD3; Joanna Ready, MD8; Suk Seo, MD9; David Witt, MD3; Michael Silverberg, PhD, MPH4
|
| |
|
|
|
|
|
